title: Complex formation by human insulin-like growth factor-binding protein-3 and human acid-labile subunit in growth hormone-deficient rats.
abstract: Insulin-like growth factor-binding protein-3 (IGFBP-3), after first associating with IGF-I or IGF-II, is able to associate with the acid-labile subunit (ALS) and form a 140-kDa complex. To investigate the factors regulating ternary complex formation in vivo, human (h) IGFBP-3, hIGF-I, and hALS were administered in various combinations to GH-deficient (dw/dw) rats. hIGFBP-3 had a complex pattern of disappearance from the rat circulation, with an initial phase lasting minutes and a prolonged phase(s) lasting hours. If coinjected with hIGF-I, significantly more hIGFBP-3 was retained over 2 h. The molecular distribution of hIGFBP-3 was determined after size-separation chromatography. After an iv bolus of hIGFBP-3, 36.1 +/- 5.0% was in the 140-kilodalton complex at 5 min; this increased to 55.1 +/- 7.1% if hIGF-I was coinjected (P < 0.05). The 140-kDa complex disappeared slowly over hours, whereas 50- and 30-kDa forms of hIGFBP-3 cleared rapidly, with half-lives of minutes. To determine the importance of ALS in regulating the molecular distribution of hIGFBP-3, hALS was coinjected. Immunoreactive hALS disappeared slowly from the circulation and was shown to retain functional activity after 2 h in vivo. Coadministration of hALS did not influence the pattern of ternary complex formation, consistent with the presence of excess endogenous rat ALS. We conclude that ALS circulates in excess even in GH deficiency, is retained in the circulation for hours, and determines the stability of the 140-kDa complex, whereas IGF-I is a limiting factor in ternary complex formation by hIGFBP-3.
authors.affiliation: Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
authors.forename: M S
authors.initials: MS
authors.lastname: Lewitt
authors.forename: H
authors.initials: H
authors.lastname: Saunders
authors.forename: J L
authors.initials: JL
authors.lastname: Phuyal
authors.forename: R C
authors.initials: RC
authors.lastname: Baxter
mesh_terms: D000818:Animals; D002352:Carrier Proteins / Q000008:administration & dosage / Q000378:metabolism*; D002845:Chromatography; D006023:Glycoproteins / Q000378:metabolism*; D013006:Growth Hormone / Q000172:deficiency*; D006207:Half-Life; D006801:Humans; D006863:Hydrogen-Ion Concentration; D018969:Insulin-Like Growth Factor Binding Proteins; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage / Q000378:metabolism; D007700:Kinetics; D008970:Molecular Weight; D051381:Rats
chemical_list: D002352:Carrier Proteins; D006023:Glycoproteins; D018969:Insulin-Like Growth Factor Binding Proteins; C075944:insulin-like growth factor binding protein, acid labile subunit; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone